Thilo Schroeder, Ph.D.
Thilo Schroeder, Ph.D. has a passion for precision medicines in cancer with a focus on identifying first and best-in-class targeted therapies regardless of drug modality. Since 2012, Thilo has helped grow and shape Nextech as a leading oncology focused venture firm.
Thilo is a board member of Revolution Medicines (NASDAQ: RVMD), IDEAYA Biosciences (NASDAQ: IDYA), PMV Pharma, Circle Pharma, Silverback Therapeutics, MOMA Therapeutics and is a board observer of BlackDiamond Therapeutics (NASDAQ: BDTX). Past board seats include Blueprint Medicines (NASDAQ: BPMC) and Peloton Therapeutics (acquired by Merck).
Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology developed by Molecular Partners (SWX:MOLN).
A family person and loving father of two, Thilo has not given up on the illusion of staying fit, and can often be found at the nearest CrossFit gym when he travels.